Page 23 - 《中国药房》2024年15期

[ 9 ] PENG Y，ZHAO Q，LIAO Z Y，et al. Efficacy and safety analysis of clinical trials[J]. BMC Cancer，2021，21（1）：
of first-line treatments for patients with advanced anapla- 1278.
stic lymphoma kinase mutated，non-small cell cancer：a [20] CHUANG C H，CHEN H L，CHANG H M，et al. Syste-
systematic review and network meta-analysis[J]. Cancer， matic review and network meta-analysis of anaplastic lym‐
2023，129（8）：1261-1275. phoma kinase （ALK） inhibitors for treatment-naïve ALK-
[10] ANDO K，MANABE R，KISHINO Y，et al. Comparative positive lung cancer[J]. Cancers （Basel），2021，13（8）：
efficacy of ALK inhibitors for treatment-naïve ALK- 1966.
positive advanced non-small cell lung cancer with central [21] ANDO K，MANABE R，KISHINO Y，et al. Comparative
nervous system metastasis：a network meta-analysis[J]. Int efficacy and safety of lorlatinib and alectinib for ALK-
J Mol Sci，2023，24（3）：2242. rearrangement positive advanced non-small cell lung can‐
[11] 王青，赵璐，吴尚，等. 劳拉替尼治疗非小细胞肺癌临床 cer in Asian and non-Asian patients：a systematic review
疗效的 Meta 分析及其安全性评价[J]. 中国医院用药评 and network meta-analysis[J]. Cancers，2021，13（15）：
价与分析，2023，23（2）：212-218. 3704.
WANG Q，ZHAO L，WU S，et al. Meta-analysis and [22] 齐冉，刘旭婷，高胜男，等. 劳拉替尼与阿来替尼一线治
safety evaluation on clinical efficacy of lorlatinib in the 疗间变性淋巴瘤激酶阳性非小细胞肺癌的药物经济学
treatment of non-small cell lung cancer[J]. Eval Anal 评价[J]. 中国药业，2023，32（5）：115-119.
Drug Use Hosp China，2023，23（2）：212-218. QI R，LIU X T，GAO S N，et al. Pharmacoeconomic
[12] WEN Y K，JIANG T，WU X R，et al. Front-line treatment evaluation of lorlatinib and alectinib in the first-line treat‐
for advanced non-small-cell lung cancer and ALK fusion： ment of anaplastic lymphoma kinase-positive non-small
a network meta-analysis[J]. Ther Adv Med Oncol，2022， cell lung cancer[J]. China Pharm，2023，32（5）：115-119.
14：17588359221116607. [23] LUO X，ZHOU Z，ZENG X H，et al. Cost-effectiveness of
[13] WANG L D，SHENG Z X，ZHANG J Y，et al. Compari‐ ensartinib，crizotinib，ceritinib，alectinib，brigatinib and
son of lorlatinib，alectinib and brigatinib in ALK inhibitor- lorlatinib in patients with anaplastic lymphoma kinase-
naive/untreated ALK-positive advanced non-small-cell positive non-small cell lung cancer in China[J]. Front Pub‐
lung cancer：a systematic review and network meta- lic Health，2022，10：985834.
analysis[J]. J Chemother，2022，34（2）：87-96. [24] GOURZOULIDIS G， ZISIMOPOULOU O，
[14] TAO J H，ZHENG C J，ZHANG C F，et al. First-line treat‐ BOUBOUCHAIROPOULOU N，et al. Cost-effectiveness
ments for patients with advanced ALK gene rearrangements analysis of lorlatinib in patients previously treated with
in NSCLC：a systematic review and network meta-analysis anaplastic lymphoma kinase inhibitors for non-small cell
[J]. J Int Med Res，2022，50（11）：3000605221132703. lung cancer in Greece[J]. J Health Econ Outcomes Res，
[15] JIANG J，ZHAO C，ZHANG F，et al. ALK inhibitors in 2022，9（1）：50-57.
ALK-rearranged non-small cell lung cancer with and with‐ [25] 孙蕾，陈平钰，马爱霞. 劳拉替尼一线治疗间变性淋巴瘤
out brain metastases：systematic review and network meta- 激酶阳性晚期非小细胞肺癌的药物经济学评价[J]. 中国
analysis[J]. BMJ Open，2022，12（9）：e060782. 药房，2022，33（9）：1102-1108.
[16] ZHAO B H，HAN Y，WANG Y D，et al. A Bayesian net‐ SUN L，CHEN P Y，MA A X. Pharmacoeconomic eva-
work meta-analysis regarding the comparative efficacy of luation of loratinib in the first-line treatment of anaplastic
therapeutics for ALK-positive，brain metastatic non-small lymphoma kinase-positive advanced non-small cell lung
cell lung cancer[J]. Pharmacol Res，2021，174：105931. cancer[J]. China Pharm，2022，33（9）：1102-1108.
[17] WU K L，CHEN H L，TSAI Y M，et al. First-line anapla- [26] NILSSON F O L，ASANIN S T，MASTERS E T，et al.
stic lymphoma kinase （ALK） inhibitors for ALK-positive The cost-effectiveness of lorlatinib versus chemotherapy
lung cancer in Asian populations：systematic review and as a second- or third-line treatment in anaplastic lym‐
network meta-analysis[J]. J Clin Med，2021，10（19）： phoma kinase （ALK）-positive non-small-cell lung cancer
4376. in Sweden[J]. Pharmacoeconomics，2021，39（8）：941-952.
[18] PENG L，LU D F，XIA Y，et al. Efficacy and safety of [27] LI S N，LI J H，PENG L B，et al. Cost-effectiveness of lor‐
first-line treatment strategies for anaplastic lymphoma latinib as a first-line therapy for untreated advanced ana‐
kinase-positive non-small cell lung cancer：a Bayesian net‐ plastic lymphoma kinase-positive non-small cell lung can‐
work meta-analysis[J]. Front Oncol，2021，11：754768. cer[J]. Front Oncol，2021，11：684073.
[19] MA H C，LIU Y H，DING K L，et al. Comparative effi‐ （收稿日期：2024-01-05 修回日期：2024-05-27）
cacy and safety of first-line treatments for advanced non- （编辑：刘明伟）
small cell lung cancer with ALK-rearranged：a meta-

中国药房 2024年第35卷第15期 China Pharmacy 2024 Vol. 35 No. 15 · 1817 ·